KRAS and non-small cell lung carcinoma: Although previous studies have indicated an association between blood afatinib maleate levels and treatment-related adverse events in NSCLCs exhibiting epidermal growth factor receptor (EGFR) mutations (7, 8), the association between sotorasib blood concentration and treatment-related adverse events in patients with NSCLC with the KRAS p.G12C mutation has not been previously reported.